We unravel complex biology with optogenetics, chemistry, and AI for small molecule therapeutic discovery.
Aging is an intrinsically complex
systems biology challenge.
Our integrated platform is
purpose-built to unravel its
intricate networks.
By combining synthetic biology,
chemistry, and AI, we probe disease
biology with unprecedented control
and precision — enabling systematic
exploration of chemical space
that was previously inaccessible.
Through the convergence of
high-fidelity biological and chemical
data with advanced AI, we unlock
new therapeutic opportunities
for age-related diseases.
Our platform enables precise, dynamic control of biological targets and pathways, generating high-fidelity datasets that, combined with advanced AI, unlock systematic exploration of previously inaccessible chemical space.
We harness light to control biology with unmatched precision, enabling selective pathway activation without off-target effects.
We apply the latest chemistry tools to optimize our drug discovery, from target validation to small molecule optimization.
We power our platform with an AI engine fueled by differentiated datasets built for the era of computational discovery.
We are advancing a pipeline of novel small molecule therapeutics by unraveling complex biology. Built on pioneering science from our co-founder at MIT, and powered by a world-class team of innovators.
Our discoveries have been featured in Nature, Nature Aging, Nature Protocols, and Cell.
In this landmark Cell publication, we unveil our first-of-a-kind optogenetic screening platform for drug discovery.
Read article →
